IONIS PHARMACEUTICALS INC — Director's Dealing 2015

Jul 17, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Regulus Therapeutics Inc. (RGLS)
CIK: 0001505512
Period of Report: 2015-07-15

Reporting Person: ISIS PHARMACEUTICALS INC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-07-15	Common Stock	S	65133	$10.762	Disposed	5451172	Direct
2015-07-16	Common Stock	S	167000	$10.7866	Disposed	5284172	Direct
2015-07-17	Common Stock	S	111000	$10.214	Disposed	5173172	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.62 to $11.05 inclusive. The reporting person undertakes to provide RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.70 to $10.99 inclusive. The reporting person undertakes to provide RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.095 to $10.765 inclusive. The reporting person undertakes to provide RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.